EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Bupropion-Induced Aseptic Meningitis: Postmarketing Safety Evaluation and Case Report

Joseph Cusimano, David Croteau, Jamie Ridley Klucken, Henry Appiah, Sheheryar Muhammad, Rajdeep Gill, Shamir Kalaria, Vicky Chan

Psychopharmacology Bulletin · 29.10.2026 · 56 (4) · 8-15

DOI: 10.64719/pb.21591 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Psychopharmacology Bulletin, online erschienen am 29.10.2026. Verfasst von Joseph Cusimano und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cusimano, PharmD, U.S. Food and Drug Administration, Division of Pharmacovigilance, Silver Spring, MD. Hauptthemen laut MEDLINE: Bupropion, Meningitis, Aseptic, Product Surveillance, Postmarketing, Antidepressive Agents, Second-Generation. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration (FDA) evaluated the association between bupropion and aseptic meningitis after detecting a safety signal during routine surveillance. Two cases of aseptic meningitis associated with bupropion were identified, including one exceedingly well-documented case that we assessed with a probable causal association with bupropion. The paucity of cases is striking given the long market duration and widespread utilization of bupropion-containing products. FDA required updates to the U.S. Prescribing Information for bupropion-containing products, as awareness of the rare, possible risk of aseptic meningitis with bupropion may prevent misdiagnosis or hospitalization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BupropionMeningitis, AsepticProduct Surveillance, PostmarketingAntidepressive Agents, Second-GenerationHumansUnited StatesFemaleUnited States Food and Drug AdministrationMaleMiddle Aged

Stichwörter der Autor:innen

asepticbupropioncase reportsdrug labelingmeningitispostmarketingproduct surveillanceunited states food and drug administration

Substanzen

BupropionAntidepressive Agents, Second-Generation

Autor:innen und Institutionen

  • Cusimano, PharmD, U.S. Food and Drug Administration, Division of Pharmacovigilance, Silver Spring, MD.
  • Croteau, MD, U.S. Food and Drug Administration, Division of Pharmacovigilance, Silver Spring, MD.
  • Klucken, PharmD, U.S. Food and Drug Administration, Division of Pharmacovigilance, Silver Spring, MD.
  • Appiah, PharmD, U.S. Food and Drug Administration, Division of Epidemiology II, Silver Spring, MD.
  • Muhammad, PharmD, U.S. Food and Drug Administration, Division of Epidemiology II, Silver Spring, MD.
  • Gill, PharmD, U.S. Food and Drug Administration, Division of Epidemiology II, Silver Spring, MD.

Zitieren

APA

Cusimano, J., Croteau, D., Klucken, J. R., Appiah, H., Muhammad, S., Gill, R., Kalaria, S., & Chan, V. (2026). Bupropion-Induced Aseptic Meningitis: Postmarketing Safety Evaluation and Case Report. Psychopharmacology Bulletin, 56(4), 8-15. https://doi.org/10.64719/pb.21591

Vancouver

Cusimano J, Croteau D, Klucken JR, Appiah H, Muhammad S, Gill R, et al. Bupropion-Induced Aseptic Meningitis: Postmarketing Safety Evaluation and Case Report. Psychopharmacology Bulletin. 2026;56(4):8-15. doi:10.64719/pb.21591

BibTeX
@article{Cusimano2026,
  author = {Cusimano, Joseph and Croteau, David and Klucken, Jamie Ridley and Appiah, Henry and Muhammad, Sheheryar and Gill, Rajdeep and Kalaria, Shamir and Chan, Vicky},
  title = {Bupropion-Induced Aseptic Meningitis: Postmarketing Safety Evaluation and Case Report},
  journal = {Psychopharmacology Bulletin},
  year = {2026},
  volume = {56},
  number = {4},
  pages = {8--15},
  doi = {10.64719/pb.21591}
}
Kostenlos starten →